Per-Se Technologies has appointed Philip Pead president and CEO following the abrupt departure of Allen Ritchie. Pead also assumes Ritchie's spot on the company's board of directors. Pead joined Per-Se in 1997 and most recently held the
Per-Se Technologies has appointed Philip Pead president and CEO following the abrupt departure of Allen Ritchie. Pead also assumes Ritchie's spot on the company's board of directors. Pead joined Per-Se in 1997 and most recently held the positions of executive vice president and COO for the firm. Per-Se provides business management services to physicians and claims to support 35,000 physicians and 2000 healthcare organizations.
© 2000 Miller Freeman Inc.
11/29/00, Issue # 117, page 5.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.